EU4Monitoring Drugs (EU4MD)

EU4MD logo

Project duration

2019-2021

Budget

€3 million

Implementing Partners

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
European Drug Report 2019
European Drug Report 2019

Brief Description

The programme will support national and regional readiness to identify and respond to drug-related security and health threats.

Countries covered: Algeria, Armenia, Azerbaijan, Belarus, Egypt, Georgia, Israel, Jordan, Lebanon, Libya, Moldova, Morocco, Palestine, Tunisia and Ukraine

Objectives

Whilst fostering regional cooperation and cooperation between the ENP and the EU, the EU4MD project will: 

- help beneficiary countries be better prepared to respond to existing and future drug-related threats through capacity-building and partnerships;

- facilitate the identification, understanding and reporting of new and emerging drug-related threats and the analysis of their implications for security and health;

- support a strategic analysis of developments in the drug market and how these impact on security and health.

Actions in brief

Networking and partnership are central to EU4MD. The project will deploy a participatory approach to capacity building (‘learning by doing’) and activities will focus on developing practical and scientific knowledge, along with the skills of professionals and organisations.

On the supply side, EU4MD will support a better understanding of drug markets; capacity development for forensic analysis; assessment of the environmental impact of drug production; identification of ‘hot spots’; mapping of production and trafficking dynamics; technological innovations; threat assessment and responses to emerging issues.

On the demand side, work will focus on identifying trends in prevalence and patterns of drug use; drug-related harms; supporting treatment, harm-reduction and prevention activities; dissemination of innovative monitoring approaches; development of gender-appropriate responses; and assessment and promotion of services for vulnerable populations.

Proven tools and methods developed by the EMCDDA will be used in order to improve drug monitoring and support the introduction of evidence-based practices to better respond to the health and social problems resulting from drug use and the drug market.

Print pdf